Some highlights from the current issue:
From the Editor: UK government announces new pricing plans
USA: Barr shareholders approve Teva merger; Watson acquires products
USA: KV provides second quarter and six month estimates
USA: Cephalon and Eurand file patent lawsuit against Mylan and Barr
USA: Eli Lilly launches duloxetine lawsuit against Impax
USA: Perrigo settles desloratadine patent litigation
USA: Dr Reddy‟s launches sumatriptan authorised generic
USA: Teva gains budesonide approval; flurry of activity results
Germany: Stada reports nine month results
Hungary: Gedeon Richter announces nine month results
Slovenia: Krka reports nine month results
UK: SFO price fixing case appeal turned down
EU: EC publishes preliminary pharma competition report
UK: Government announces new drug price deal
India: PharmaZell opens production plant
Algeria: Actavis announces partnership
UAE: ProStrakan and NewBridge sign MEA agreement

Some highlights from the current issue:
EU issues GCSF final approvals
Insmed presents G-CSF bioequivalence results
Orrin Hatch urges passage of S. 1695, Henry Waxman urges caution
UK lists EPO biosimilars in the British National Formulary

Partnering in the Global Generics Industry 2008: A guide to companies
Published July 2008
For everyone needing to evaluate the generic industry’s competitive landscape, this new, thoroughly researched 406-page report is an essential business reference.

Opportunities and Challenges for Generic Drugs in Australia
Published March 2008
This report provides a complete assessment of the US$1.43 billion Australian generic pharmaceutical market.

The World Generic Market Report 2008
Published December 2007
This new 2 volume, 700 page edition is packed with facts, figures, analysis and statistics, that provides the most thorough analysis available on generic markets, products and companies and the issues they face.

Emerging Opportunities for Inhalation & Nasal Spray Generic Drugs 2008
Published October 2008
This report provides a complete review of the emerging opportunities and operating environment for inhalation and nasal spray drugs. It reviews products currently available generically and assesses the prospects for those durgs losing patent protection over the next ten years.

Biosimilars: A viable market - but when?
Published September 2008
The promise of profits from biosimilars grows greater, but only when a number of significant market, regulatory and clinical hurdles can be overcome. This critical 200-page management report addresses key issues of concern.

Injectable Generic Drugs : Prospects & Opportunities to 2013
Published July 2008
This report will provide industry planners, commercial developers and the investment community with a thorough review of the operating landscape for generic injectables. The report is packed with primary source information and market forecasts, and takes a balanced view of the players and products that will shape this high value market sector.

CNS Generic Drugs: Prospects & Opportunities to 2012
Published April 2008
This important new strategic report from Espicom evaluates the CNS generic drug market and provides detailed assessment and forecast for leading products by value to 2012, patent expiry opportunities to 2015 and competitive evaluation.

The latest business and market news and developments from around the world
Company plans, deals, developments and performance
The operating environments in major generic markets
New generic drug opportunities by therapy & delivery mechanism
A flexible service to suit every need & budget

Patent Information:

Pipeline™ Selector Patent Reports